Literature DB >> 2446742

Augmentation of activity of cis-diamminedichloroplatinum(II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice.

N T Sklarin1, A P Chahinian, E J Feuer, L A Lahman, L Szrajer, J F Holland.   

Abstract

Two human mesothelioma xenograft lines, BG and ES, serially passaged in athymic mice, were studied to determine the efficacy of alpha-interferon in this type of tumor. Treatment began after progressive tumor growth was established. Recombinant human alpha-interferon-2a (Roferon- A) was given by s.c. injection, at a site distant from the tumor, at a dose of 2 x 10(5) IU 5 days per wk for 5 wk. Mild inhibitory activity was noted in both lines with interferon alone. cis-Diamminedichloroplatinum(II) (CDDP) (4 mg/kg) weekly x 5 was effective in line BG, while mitomycin C (1.5 mg/kg) weekly x 3 was effective in line ES. CDDP was not as effective in line ES. The moderate activity of CDDP in line BG and of mitomycin C in line ES was markedly increased by the addition of alpha-interferon. The combination of mitomycin C and alpha-interferon was as effective as mitomycin C and CDDP. No additional toxicity was noted by the addition of alpha-interferon. The combination of recombinant human alpha-interferon-2a and active chemotherapeutic agents is effective in mesothelioma xenografts.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2446742

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction.

Authors:  H W Pass; B K Temeck; K Kranda; S M Steinberg; H I Pass
Journal:  Ann Surg Oncol       Date:  1995-05       Impact factor: 5.344

Review 3.  Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance.

Authors:  G J Sewell
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

4.  Treatment of a patient with malignant mesothelioma with interferon-alpha 2 based on in vitro sensitivity tests.

Authors:  V Sexl; L Wagner; M Wiesholzer; E Presterl; W Base
Journal:  Clin Investig       Date:  1994-03

5.  Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia.

Authors:  Mustafa Altinbas; Ozlem Er; Metin Ozkan; Hasan Senol Coskun; Inci Gulmez; Eyup Ekici; Bunyamin Kaplan; Bulent Eser; Mustafa Ozesmi
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

6.  A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum.

Authors:  K Dhingra; M Talpaz; H M Dhingra; J A Ajani; J M Rothberg; J U Gutterman
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

7.  Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study.

Authors:  E E Vokes; D J Haraf; P C Hoffman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  A pituitary gene encodes a protein that produces differentiation of breast and prostate cancer cells.

Authors:  Micsunica Platica; Elena Ivan; James F Holland; Alin Ionescu; Sheryl Chen; John Mandeli; Pamela D Unger; Ovidiu Platica
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

9.  Effects of natural interferon alpha, natural tumor necrosis factor alpha and their combination on human mesothelioma xenografts in nude mice.

Authors:  T Ohnuma; L Szrajer; J F Holland; M Kurimoto; J Minowada
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

10.  A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.

Authors:  E E Vokes; D J Haraf; L C Drinkard; P C Hoffman; M K Ferguson; N J Vogelzang; S Watson; N J Lane; H M Golomb
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.